NASDAQ:AXGN AxoGen (AXGN) Stock Price, News & Analysis $13.02 -0.23 (-1.74%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$12.78▼$13.3550-Day Range$7.52▼$13.2552-Week Range$3.45▼$13.35Volume301,301 shsAverage Volume397,218 shsMarket Capitalization$569.04 millionP/E RatioN/ADividend YieldN/APrice Target$13.80 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get AxoGen alerts: Email Address AxoGen MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside6.0% Upside$13.80 Price TargetShort InterestHealthy4.12% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.84Based on 7 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.33) to ($0.18) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.09 out of 5 starsMedical Sector742nd out of 910 stocksElectromedical Equipment Industry15th out of 22 stocks 1.5 Analyst's Opinion Consensus RatingAxoGen has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAxoGen has only been the subject of 3 research reports in the past 90 days.Read more about AxoGen's stock forecast and price target. Previous Next 4.0 Short Interest Percentage of Shares Shorted4.12% of the outstanding shares of AxoGen have been sold short.Short Interest Ratio / Days to CoverAxoGen has a short interest ratio ("days to cover") of 4.1.Change versus previous monthShort interest in AxoGen has recently decreased by 8.16%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAxoGen does not currently pay a dividend.Dividend GrowthAxoGen does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for AXGN. Previous Next 3.8 News and Social Media Coverage News SentimentAxoGen has a news sentiment score of 0.84. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for AxoGen this week, compared to 2 articles on an average week.Search Interest6 people have searched for AXGN on MarketBeat in the last 30 days. MarketBeat Follows2 people have added AxoGen to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, AxoGen insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.00% of the stock of AxoGen is held by insiders.Percentage Held by Institutions80.29% of the stock of AxoGen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about AxoGen's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for AxoGen are expected to grow in the coming year, from ($0.33) to ($0.18) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of AxoGen is -26.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of AxoGen is -26.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAxoGen has a P/B Ratio of 5.97. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about AxoGen's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad True Gold RepublicChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a population of over 1.4 BILLION is “buying gold like there’s no tomorrow,” according to The New York Times. China, a rising global economic threat, aims to reduce its dependence on the US dollar… . Click here now to get your free 'De-Dollarization' Guide. About AxoGen Stock (NASDAQ:AXGN)AxoGen, Inc., together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and AxoTouch two-point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. The company provides its products to hospitals, surgery centers, and military hospitals, plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. AxoGen, Inc. is headquartered in Alachua, Florida.Read More AXGN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AXGN Stock News HeadlinesSeptember 6 at 7:00 AM | globenewswire.comAxogen Completes Submission of Biologics License Application to U.S. Food and Drug Administration for Avance Nerve Graft®September 6 at 1:13 AM | americanbankingnews.comAnalysts Set AxoGen, Inc. (NASDAQ:AXGN) Target Price at $13.80September 7, 2024 | Behind the Markets (Ad)⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.September 4 at 1:36 AM | markets.businessinsider.comAxogen Reports Inducement Grant to New Employee Under NASDAQ Listing Rule 5635(C)(4)August 14, 2024 | finance.yahoo.comAXGN Sep 2024 15.000 call (AXGN240920C00015000)August 11, 2024 | nz.finance.yahoo.comAxoGen Second Quarter 2024 Earnings: Beats ExpectationsAugust 10, 2024 | markets.businessinsider.comBuy Rating Affirmed for AxoGen: Strong Q2 Performance and Strategic Leadership Amidst Market Growth PotentialAugust 9, 2024 | markets.businessinsider.comBuy Rating Affirmed for AxoGen Amid Strong Q2 Performance and Positive Growth OutlookSeptember 7, 2024 | Behind the Markets (Ad)⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.August 9, 2024 | seekingalpha.comApple, Inc. (AXGN) Q2 2024 Earnings Call TranscriptAugust 8, 2024 | markets.businessinsider.comAxogen, Inc. Reports Second Quarter 2024 Financial ResultsAugust 8, 2024 | globenewswire.comAxogen, Inc. Announces New Leadership AppointmentsAugust 7, 2024 | markets.businessinsider.comAxoGen earnings preview: what to expectAugust 1, 2024 | nz.finance.yahoo.comAxoGen, Inc. (0HKD.L)July 23, 2024 | globenewswire.comAxogen, Inc. to Report Second Quarter 2024 Financial Results and Host Conference Call on August 8, 2024July 20, 2024 | sg.finance.yahoo.comAxoGen, Inc. (AXGN) stock historical prices & data – Yahoo FinanceJuly 1, 2024 | globenewswire.comCompany Reports Inducement Grants to Non-Executive New Employee Under Nasdaq Listing Rule 5635(C)(4)June 24, 2024 | globenewswire.comAxogen, Inc Announces Full Launch of Avive+ Soft Tissue Matrix™See More Headlines Receive AXGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AxoGen and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/08/2024Today9/07/2024Next Earnings (Estimated)11/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Electromedical equipment Sub-IndustryMedical Equipment Current SymbolNASDAQ:AXGN CUSIPN/A CIK805928 Webwww.axogeninc.com Phone(386) 462-6800Fax386-462-6801Employees450Year FoundedN/APrice Target and Rating Average Stock Price Target$13.80 High Stock Price Target$20.00 Low Stock Price Target$9.00 Potential Upside/Downside+6.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($0.50) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-21,720,000.00 Net Margins-9.53% Pretax Margin-9.53% Return on Equity-17.30% Return on Assets-8.63% Debt Debt-to-Equity Ratio0.70 Current Ratio3.51 Quick Ratio2.32 Sales & Book Value Annual Sales$173.48 million Price / Sales3.28 Cash FlowN/A Price / Cash FlowN/A Book Value$2.18 per share Price / Book5.97Miscellaneous Outstanding Shares43,705,000Free Float40,646,000Market Cap$569.04 million OptionableOptionable Beta1.11 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for September 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMs. Karen Zaderej (Age 62)Chairman, President & CEO Comp: $1.49MMr. Erick DeVinney (Age 48)Chief Innovation Officer Comp: $557.9kMr. Harold D. TamayoVice President of Finance & Investor RelationsMr. Marc A. Began (Age 56)Executive VP, General Counsel & Chief Compliance Officer Ms. Doris QuackenbushVice President of SalesMr. Jens Schroeder KempChief Marketing OfficerDr. Ivica Ducic M.D.Ph.D., Chief Medical OfficerMore ExecutivesKey CompetitorsCuteraNASDAQ:CUTRNatus MedicalNASDAQ:NTUSIntegra LifeSciencesNASDAQ:IARTCONMEDNYSE:CNMDiRhythm TechnologiesNASDAQ:IRTCView All CompetitorsInsiders & InstitutionsPerceptive Advisors LLCSold 1,523,508 shares on 8/16/2024Ownership: 0.070%Millennium Management LLCSold 634,391 shares on 8/15/2024Ownership: 1.560%First Light Asset Management LLCBought 2,578,147 shares on 8/14/2024Ownership: 7.651%Cubist Systematic Strategies LLCSold 29,134 shares on 8/14/2024Ownership: 0.206%Squarepoint Ops LLCBought 39,624 shares on 8/14/2024Ownership: 0.139%View All Insider TransactionsView All Institutional Transactions AXGN Stock Analysis - Frequently Asked Questions How have AXGN shares performed this year? AxoGen's stock was trading at $6.83 at the beginning of the year. Since then, AXGN stock has increased by 90.6% and is now trading at $13.02. View the best growth stocks for 2024 here. How were AxoGen's earnings last quarter? AxoGen, Inc. (NASDAQ:AXGN) announced its quarterly earnings results on Thursday, August, 8th. The medical equipment provider reported ($0.04) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.14) by $0.10. The medical equipment provider earned $47.91 million during the quarter, compared to analysts' expectations of $43.27 million. AxoGen had a negative net margin of 9.53% and a negative trailing twelve-month return on equity of 17.30%. What is Karen Zaderej's approval rating as AxoGen's CEO? 19 employees have rated AxoGen Chief Executive Officer Karen Zaderej on Glassdoor.com. Karen Zaderej has an approval rating of 100% among the company's employees. This puts Karen Zaderej in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 83.0% of employees surveyed would recommend working at AxoGen to a friend. Who are AxoGen's major shareholders? Top institutional investors of AxoGen include First Light Asset Management LLC (7.65%), Assenagon Asset Management S.A. (3.00%), Divisadero Street Capital Management LP (1.57%) and Millennium Management LLC (1.56%). Insiders that own company stock include Karen L Zaderej, Gregory Gene Freitag, Erick Wayne Devinney, Amy Mcbride Wendell, Guido J Neels, Peter J Mariani, Michael Patrick Donovan and William P Mr Burke. View institutional ownership trends. How do I buy shares of AxoGen? Shares of AXGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of AxoGen own? Based on aggregate information from My MarketBeat watchlists, some other companies that AxoGen investors own include Advanced Micro Devices (AMD), Bank of America (BAC), Intelsat (I), Intel (INTC), Micron Technology (MU), Xilinx (XLNX) and Corbus Pharmaceuticals (CRBP). This page (NASDAQ:AXGN) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredMy grim warning about AI stocksToday, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S....Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AxoGen, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AxoGen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AXGN Stock Alerts